Business
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Investor's Business Daily

What the report says
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Two ‘Dancing Generals’ arrested as intelligence probe widensThe Independent Uganda
Former CMI commanders Kandiho, Bakahumura arrested over false intelThe Observer
Uganda, Nigeria Seek Stronger Business Ties Under AfCFTASoftPower News